These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 9137910

  • 21. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP, Piercey MF.
    J Neurol Sci; 1999 Feb 01; 163(1):25-31. PubMed ID: 10223406
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
    Lorenc-Koci E, Wolfarth S.
    Eur J Pharmacol; 1999 Nov 26; 385(1):39-46. PubMed ID: 10594343
    [Abstract] [Full Text] [Related]

  • 23. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH.
    J Pharmacol Exp Ther; 2005 Jul 26; 314(1):310-9. PubMed ID: 15833897
    [Abstract] [Full Text] [Related]

  • 24. Occurrence of yawning and decrease of prolactin levels via stimulation of dopamine D2-receptors after administration of SND 919 in rats.
    Matsumoto S, Yamada K, Nagashima M, Domae M, Shirakawa K, Furukawa T.
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul 26; 340(1):21-5. PubMed ID: 2571944
    [Abstract] [Full Text] [Related]

  • 25. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD, Harting J, Minck KO.
    J Pharmacol Exp Ther; 1996 Jan 26; 276(1):41-8. PubMed ID: 8558454
    [Abstract] [Full Text] [Related]

  • 26. Motor effects of lamotrigine in naive and dopamine-depleted mice.
    Kaur S, Starr M.
    Eur J Pharmacol; 1996 May 23; 304(1-3):1-6. PubMed ID: 8813577
    [Abstract] [Full Text] [Related]

  • 27. The effect of repeated treatment with pramipexole on the central dopamine D3 system.
    Maj J, Rogói Z, Margas W, Kata M, Dziedzicka-Wasylewska M.
    J Neural Transm (Vienna); 2000 May 23; 107(12):1369-79. PubMed ID: 11458990
    [Abstract] [Full Text] [Related]

  • 28. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN, Woolsey C, Ryoo H, Borwege S, Hagner D.
    BMC Biol; 2004 Oct 11; 2():22. PubMed ID: 15473914
    [Abstract] [Full Text] [Related]

  • 29. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; turning behaviour.
    Koshikawa N, Kitamura M, Kobayashi M, Cools AR.
    Eur J Pharmacol; 1996 Jul 25; 308(3):235-41. PubMed ID: 8858293
    [Abstract] [Full Text] [Related]

  • 30. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
    Kaur S, Starr MS.
    Eur J Pharmacol; 1995 Jul 04; 280(2):159-66. PubMed ID: 7589181
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.
    Kosmowska B, Wardas J, Głowacka U, Ananthan S, Ossowska K.
    CNS Neurosci Ther; 2016 Jan 04; 22(1):53-62. PubMed ID: 26459182
    [Abstract] [Full Text] [Related]

  • 33. Dopaminergic modulation of rat pup ultrasonic vocalizations.
    Dastur FN, McGregor IS, Brown RE.
    Eur J Pharmacol; 1999 Oct 08; 382(2):53-67. PubMed ID: 10528139
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.
    Piercey MF, Hyslop DK, Hoffmann WE.
    Brain Res; 1997 Jul 11; 762(1-2):19-28. PubMed ID: 9262154
    [Abstract] [Full Text] [Related]

  • 36. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist.
    Smith HP, Nichols DE, Mailman RB, Lawler CP.
    Eur J Pharmacol; 1997 Mar 26; 323(1):27-36. PubMed ID: 9105873
    [Abstract] [Full Text] [Related]

  • 37. Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats.
    Kurashima M, Yamada K, Nagashima M, Shirakawa K, Furukawa T.
    Pharmacol Biochem Behav; 1995 Nov 26; 52(3):503-8. PubMed ID: 8545466
    [Abstract] [Full Text] [Related]

  • 38. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S.
    J Pharmacol Exp Ther; 1995 Jul 26; 274(1):329-36. PubMed ID: 7616416
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, Hashida H, Kubo S, Suzuki M, Nanri K, Matsumura M, Murakami H, Hattori N, Tokyo Parkinson's Disease Study Group.
    Intern Med; 2013 Jul 26; 52(3):325-32. PubMed ID: 23370739
    [Abstract] [Full Text] [Related]

  • 40. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov 26; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.